DexCom
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationa...
Latest News
3 days ago · zacks.com
Here's Why You Should Retain DexCom Stock in Your Portfolio for NowDexCom's G7 15 Day adoption, international expansion and margin gains support its growth prospects, though competition and rising investments pose challenges.
6 days ago · businesswire.com
Dexcom Announces Upcoming Conference PresentationSAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026.The live presentation is scheduled to begin at approximately 2:00 PM GMT (9:00 AM EST) and will be concurrently webcast.Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference.About DexCom, Inc.
14 days ago · zacks.com
DexCom to Launch 15-Day G7 CGM System in Canada This NovemberDXCM's upcoming Canadian launch of the G7 15 Day CGM, offering longer sensor wear and improved convenience, could boost international growth and patient access.
15 days ago · seekingalpha.com
DexCom: Improving Patient Access Makes It A Long-Term BuyDXCM's recurring sensor model synergizes nicely with wider diabetes access thanks to Medicare. In fact, broader Medicare coverage could expand their overall addressable market, as long as DXCM is able to execute on that expanded opportunity. Also, DXCM now offers longer-wear sensors, and they intend to increase their manufacturing scale. So, those factors combined could improve margins as well.
18 days ago · zacks.com
DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins RiseDXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.
18 days ago · seekingalpha.com
DexCom, Inc. (DXCM) Q3 2026 Earnings Call TranscriptDexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript
18 days ago · marketbeat.com
What DexCom (DXCM) Said on Its Q3 Earnings CallDexCom NASDAQ: DXCM reported third-quarter 2026 revenue of $1.34 billion, up 11% from a year earlier on both a reported and organic basis, as U.S. growth, market-share gains and manufacturing improvements supported higher profitability.
18 days ago · zacks.com
DexCom (DXCM) Surpasses Q3 Earnings and Revenue EstimatesDexCom (DXCM) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.61 per share a year ago.
18 days ago · benzinga.com
DexCom Q3 2026 Earnings Call TranscriptDexCom (NASDAQ:DXCM) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
18 days ago · investors.com
Diabetes Wearable-Maker Handily Beats Earnings Views, Hikes Sales GuideDiabetes wearables-maker Dexcom topped third-quarter earnings forecasts Thursday and reported in-line sales. Dexcom stock was little moved.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove DXCM